Search
Search Results
##search.searchResults.foundPlural##
-
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2418PDF: 890HTML: 1707Figure 1: 259Table 1: 258 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1214PDF: 1243Suppl. Files: 606HTML: 109 -
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA
1753PDF: 699HTML: 2453 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2422PDF: 1128HTML: 2034Characteristic of study group: 251 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2121PDF: 834HTML: 733Table1: patient's characteristics: 241Table 2: profile of each patient: 234 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1908PDF: 647HTML: 370 -
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2434PDF: 1072HTML: 7711Untitled: 329Fig2: 229Fig3: 224Fig4: 246 -
Magnusiomyces capitatus Breakthrough Infection in Allogeneic Hematopoietic Cell Transplant Recipients Receiving Echinocandin Prophylaxis: Clinical Features, Management, and Review of the Literature
110PDF: 201Suppl. Files: 36Html: 118Html Suppl. Files: 95 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277885PDF: 1898HTML: 3911 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
608PDF: 303HTML: 153 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2446PDF: 2162HTML: 242 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1587PDF: 1013HTML: 266 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2715PDF: 877HTML: 5395 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
2091PDF: 881HTML: 264 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
2023PDF: 1106HTML: 261 -
Osteolytic bone lesions – A rare presentation of AML M6.
2095PDF: 1211HTML: 8013Untitled: 251 -
CANDIDEMIA IN PATIENTS WITH ACUTE LEUKEMIA: ANALYSIS OF SEVEN YEARS’ EXPERIENCE AT A SINGLE CENTER IN CHINA Candidemia in acute Leukemia
1872PDF: 1004HTML: 270 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1617PDF: 867Suppl. Files: 369Html: 173 -
OLDER ADULTS WITH PH NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A MONOCENTRIC EXPERIENCE ON CONSECUTIVE PATIENTS AGED MORE THAN 55 YEARS Older Adults with Ph Negative Acute Lymphoblastic Leukemia
1470PDF: 646Suppl. Files: 396HTML: 184 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2476PDF: 1065HTML: 2237 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4607PDF: 1832HTML: 1130 -
DISTRIBUTION OF DIFFERENT PML/RAR? BCR ISOFORMS IN INDIAN ACUTE PROMYELOCYTIC LEUKAEMIA (APL) PATIENTS AND CLINICOHEMATOLOGICAL CORRELATION
1683PDF: 984HTML: 2261Response to reviewers comments: 236 -
-
CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
3448PDF: 979HTML: 1558Fig.1 CHL-R paper: 268Fig 2 CHL-R paper: 305 -
DONOR KIR3DL1/RECEPTOR HLA-BW4-80I COMBINATION REDUCES ACUTE LEUKEMIA RELAPSE AFTER UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION KIR3DL1 with HLA-Bw4-80I reduces leukemia relapse
1545PDF: 634HTML: 250







